Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

(2015) Melinda L. Telli et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

(2015) William M. Sikov et al.   JOURNAL OF CLINICAL ONCOLOGY

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

(2015) Steven J. Isakoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

(2014) Chris Twelves et al.   BREAST CANCER RESEARCH AND TREATMENT

CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin

(2014) Elizabeth Tarasewicz et al.   CANCER BIOLOGY & THERAPY

Inhibition of CDK-mediated phosphorylation of Smad3 results in decreased oncogenesis in triple negative breast cancer cells

(2014) Elizabeth Tarasewicz et al.   CELL CYCLE

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

(2014) Gunter von Minckwitz et al.   LANCET ONCOLOGY

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

(2013) E H Lips et al.   BRITISH JOURNAL OF CANCER

Aging is not programmed

(2013) Mikhail V Blagosklonny   CELL CYCLE

MTOR-driven quasi-programmed aging as a disposable soma theory: Blind watchmaker vs. intelligent designer

(2013) Mikhail V Blagosklonny   CELL CYCLE

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

(2012) V Abkevich et al.   BRITISH JOURNAL OF CANCER

Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation

(2012) T. Popova et al.   CANCER RESEARCH

Phospho-specific Smad3 signaling

(2012) Elizabeth Tarasewicz et al.   CELL CYCLE

Apocrine Carcinoma as Triple-negative Breast Cancer: Novel Definition of Apocrine-type Carcinoma as Estrogen/Progesterone Receptor-negative and Androgen Receptor-positive Invasive Ductal Carcinoma

(2012) Y. Tsutsumi   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents

(2012) Nicolai J. Birkbak et al.   Cancer Discovery

Examining the role of cyclin D1 in breast cancer

(2011) Marco A Velasco-Velázquez et al.   Future Oncology

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

(2010) M. Graeser et al.   CLINICAL CANCER RESEARCH

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability

(2009) Jennifer A. Smith et al.   BIOCHEMISTRY

Pin1 Down-regulates Transforming Growth Factor-β (TGF-β) Signaling by Inducing Degradation of Smad Proteins

(2009) Ayako Nakano et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pin1 Promotes Transforming Growth Factor-β-induced Migration and Invasion

(2009) Isao Matsuura et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase II Trials inJournal of Clinical Oncology

(2009) Stephen A. Cannistra   JOURNAL OF CLINICAL ONCOLOGY

Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy

(2009) Tomasz Byrski et al.   JOURNAL OF CLINICAL ONCOLOGY